An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.
- Sponsor
- Nanfang Hospital, Southern Medical University
- Study ID
- NCT06753721
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Advanced Colorectal Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Doxorubicin liposome combined with CapOX and Bevacizumab — DRUGBevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
Study Details
This is a prospective, single-arm clinical study designed to evaluate the 6-month progression-free survival rate (6-month PFS rate) of Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment for advanced colorectal adenocarcinoma with SMAD4R361H/C mutation. The study plans to recruit 13 patients. After receiving 8 cycles of induction therapy, patients whose efficacy is evaluated as complete response (CR), partial response (PR), or stable disease (SD) (according to RECIST 1.1) will enter maintenance therapy.
Key Dates
- First listed
- Dec 31, 2024
- Start date
- Dec 31, 2024
- Status verified
- Dec 2024
- Primary completion
- Jun 30, 2026
- Completion
- Jun 1, 2027
Study Design
- Enrollment
- 13 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment6-month progression-free survival rate (6-month PFS rate) of Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment for advanced colorectal adenocarcinoma with SMAD4R361H/C mutation.
Primary Outcome Measure
6-month progression-free survival (PFS) [ Time Frame: 3 years ]
Central Contacts
- shi min MD,PHD86-20-62787731
Related Studies
- Engage Psychosocial Intervention for Cancer SymptomsRecruiting · Duke University · Durham, North Carolina
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3PHASE2 · Recruiting · City of Hope Medical Center · Goodyear, Arizona